Roche Breast Cancer Drug Appears to Greatly Extend Patients’ Lives
Sunday, September 28, 2014 - 09:20
in Health & Medicine
Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer.